Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 5,779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Decatur, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 2:37 AM EDT
Terminated Phase 1 Interventional

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

NCT05652868
View directory record Official record
Conditions
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Interventions
MYTX-011
Drug
Lead sponsor
Mythic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Mobile CHESS Research on Emergency Medical Services for Children

NCT00993590
View directory record Official record
Conditions
Asthma
Interventions
M CHESS
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 18 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

NCT01685060
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 29, 2026, 2:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 29, 2026, 2:37 AM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Results available

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

NCT04879849
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
Interventions
Pembrolizumab, TAK-676, Image-guided radiation therapy
Drug · Radiation
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 29, 2026, 2:37 AM EDT
Terminated Phase 3 Interventional Results available

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

NCT00673049
View directory record Official record
Conditions
Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell
Interventions
CP 751,871 (Figitumumab), Erlotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
69
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Lakeport, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00655655
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Results available

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

NCT01831089
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Interventions
PM01183 + paclitaxel +/- bevacizumab
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Not applicable Interventional

A Community Health Worker Home Intervention to Improve Pediatric Asthma Outcomes

NCT01003340
View directory record Official record
Conditions
Asthma
Interventions
Wee Wheezers
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
2 Years to 9 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 29, 2026, 2:37 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

NCT04610684
View directory record Official record
Conditions
Small-cell Lung Cancer, Brain Metastases
Interventions
Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
Jeffrey Clarke
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • Anderson, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 29, 2026, 2:37 AM EDT
Recruiting Phase 1 Interventional

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138
View directory record Official record
Conditions
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
Interventions
Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

A Study of IBI363 in Subjects with Advanced Solid Malignancies

NCT06281678
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Interventions
IBI363
Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 29, 2026, 2:37 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

NCT02393625
View directory record Official record
Conditions
ALK-positive NSCLC
Interventions
Ceritinib (LDK378), Nivolumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
4
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 3 Interventional

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

NCT00003884
View directory record Official record
Conditions
Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
zoledronic acid, quality-of-life assessment
Drug · Procedure
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
55
States / cities
Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 29, 2026, 2:37 AM EDT
Recruiting No phase listed Observational

GEMINI-NSCLC: NSCLC Biomarker Study

NCT05236114
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
58
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 29, 2026, 2:37 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

NCT07285148
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions
ANS014004 + PLB1004, ANS014004 + Osimertinib
Drug
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 29, 2026, 2:37 AM EDT
Completed No phase listed Observational

Exercise-Induced Bronchospasm in Cystic Fibrosis

NCT00806455
View directory record Official record
Conditions
Cystic Fibrosis, Bronchospasm
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

NCT04314089
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
GT103
Drug
Lead sponsor
Edward Patz
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Celebration, Florida • Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Results available

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View directory record Official record
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

NCT02913443
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
RO7051790
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 29, 2026, 2:37 AM EDT